These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Editorial comment to short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Gravas S Int J Urol; 2010 Oct; 17(10):875. PubMed ID: 20887633 [No Abstract] [Full Text] [Related]
26. [Influence of gestagens on the symptoms of prostatic hypertrophy]. Graber P; Leibundgut B Urologe A; 1972 Nov; 11(6):326-9. PubMed ID: 4118967 [No Abstract] [Full Text] [Related]
27. [Long-term outcomes of the use of α-blockers tamsulosin in men with lower urinary tract symptoms and benign prostatic hyperplasia]. Krivoborodov GG; Tur EI Urologiia; 2014; (6):47-8, 50. PubMed ID: 25799727 [TBL] [Abstract][Full Text] [Related]
28. Medical treatment of prostatic obstruction. An objective assessment. Claridge M Invest Urol; 1975 Mar; 12(5):401-4. PubMed ID: 46221 [TBL] [Abstract][Full Text] [Related]
29. [Correction of urination disorders caused by benign prostatic hyperplasia in cardiac surgery]. Koraev KN Khirurgiia (Mosk); 2003; (1):19-21. PubMed ID: 12645203 [TBL] [Abstract][Full Text] [Related]
30. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. Crawford ED BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729 [No Abstract] [Full Text] [Related]
31. [Therapeutic efficacy of sitosterin prostate capsules in prostatic adenoma and prostatitis. Results of a field study]. Dörner G; Fritsche C ZFA (Stuttgart); 1982 Jan; 58(3):167-9. PubMed ID: 6176081 [No Abstract] [Full Text] [Related]
32. Experience with the Peponen capsule in the management of benign prostatic hyperplasia. Hamvas A; Corradi G; Hegedüs M; Frang D Int Urol Nephrol; 1991; 23(1):51-5. PubMed ID: 1718920 [TBL] [Abstract][Full Text] [Related]
33. Serenoa repens and benign prostatic hyperplasia: no more effective than placebo. Prescrire Int; 2010 Aug; 19(108):181-2. PubMed ID: 20941857 [TBL] [Abstract][Full Text] [Related]
34. [Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia]. Danilov VV; Danilova TI; Danilov VV; Danilov VV Urologiia; 2013; (5):55-8. PubMed ID: 24437242 [TBL] [Abstract][Full Text] [Related]
35. [On the effects of oral administration of medroxyprogesterone acetate on urination disorders due to prostatic hypertrophy]. Valentino RV; Alberti C Recenti Prog Med; 1969 Sep; 47(3):XXI-XXXV. PubMed ID: 4099290 [No Abstract] [Full Text] [Related]
36. How many drugs for LUTS due to BPH are too many? Andersson KE J Urol; 2008 Sep; 180(3):811-2. PubMed ID: 18635235 [No Abstract] [Full Text] [Related]
37. [The action of different forms of hormone therapy in prostatic adenoma]. Délivéliotis A; Rodis N J Urol Nephrol (Paris); 1968 Mar; 74(3):211-22. PubMed ID: 4171642 [No Abstract] [Full Text] [Related]
38. The impact of alpha1-adrenoceptors on prostate cancer growth. Stamatiou K; Skolarikos A; Sofras F Urology; 2008 Apr; 71(4):756-7. PubMed ID: 18291511 [No Abstract] [Full Text] [Related]
40. [Latest contribution concerning the use of mepartricin in adenoma of the prostate]. Comar OB; Di Rienzo A Minerva Urol Nefrol; 1988; 40(2 Suppl):30-2. PubMed ID: 2460944 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]